FDA Determines Regulatory Review Period for Albunex Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Albunex, a medical device, as required by law, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.